missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human RNaseL (aa 605-733) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (62%), Rat (62%). This recombinant protein control fragment may be used for blocking experiments. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
A virally induced endoribonuclease, RNase L is the terminal factor of the anti-viral action of interferon. Activation of RNase L results in inhibition of viral proliferation. Activation of RNase L has also been determined to degrade RNA, thus, initiating a cellular stress response, inducing apoptosis. Since mutations in RNase L relate to an increased incidence of prostate cancer, the activation of RNase L functions in counteracting prostate cancer, via apoptosis.
Specifications
Specifications
| Accession Number | Q05823 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 6041 |
| Name | Human RNaseL (aa 605-733) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | 2',5'-oligoisoadenylate synthetase-dependent; 2-5 A-dependent ribonuclease; 2-5 A-dependent RNAase; 2-5 A-dependent RNase; E230029I04Rik; I79_009550; interferon-induced 2-5 A-dependent RNase; PRCA1; Ribonuclease 4; ribonuclease L; ribonuclease L (2 5-oligoisoadenylate synthetase-dependent); ribonuclease L (2', 5'-oligoisoadenylate synthetase-dependent); ribonuclease L (2, 5-oligoisoadenylate synthetase-dependent); ribonuclease L (2',5'-oligoisoadenylate synthetase-dependent); RNase L; Rnasel; RNS4 |
| Common Name | RNaseL |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction